Show summary Hide summary
When the founder of Race to Erase MS speaks about the fight against multiple sclerosis, she carries both institutional authority and personal urgency. In a recent conversation, she outlined concrete scientific gains and the continuing gaps that shape treatment, research funding and daily life for people living with the disease.
The organization she started has long combined celebrity fundraising with targeted investment in labs; now, its founder says, those investments are showing returns—but not evenly, and not yet at the scale patients need.
Where progress is visible
Over the last decade, advances in diagnostics and therapy have changed the outlook for many people with multiple sclerosis. Treatments that slow disease progression and reduce relapses are more effective than earlier options, while imaging and biomarkers have improved clinicians’ ability to track activity.
Trump moves to shield IRS from $10B liability over leaked tax returns
Stephen A. Smith, Skip Bayless back on First Take: what viewers should expect
Still, the founder emphasized that progress is incremental. “We’re seeing real steps forward in limiting damage,” she noted, “but turning that into reliable repair remains the central scientific hurdle.” That distinction—between controlling active disease and restoring lost function—frames much of current research funding and advocacy work.
Why this matters now
Better disease control has real implications for work, family life and independence, especially as therapies push the onset of disabling progression further out. For readers, the takeaway is practical: earlier diagnosis and access to the right medication can meaningfully change long-term outcomes.
At the same time, new therapeutic classes and clinical trials mean patients and clinicians face more choices—and tougher decisions about risks, costs and timing.
- Reduced relapse rates: Modern disease-modifying therapies limit relapses more reliably than older drugs, improving short-term stability.
- B-cell therapies: Treatments targeting B lymphocytes have reshaped relapse management but raise questions about long-term safety and immune recovery.
- Remyelination research: Scientists are pursuing strategies to repair myelin and restore function; early-stage trials offer cautious optimism.
- Biomarkers and imaging: Better tools are making individualized treatment more feasible, but broad clinical adoption is still uneven.
Personal stakes: advocacy from the inside
What gives the founder’s message added weight is that she speaks as both an advocate and someone affected by MS in a personal way. That dual perspective, she says, shapes how Race to Erase MS prioritizes grants and public programs—focusing on interventions that shorten the path from discovery to patient care.
She also highlighted the emotional labor of living with a chronic illness while leading a high-profile nonprofit: balancing fundraising demands, scientific oversight and unpredictable health days. Those details matter to donors and policymakers, she argued, because they clarify why flexible, sustained funding matters more than one-off contributions.
Barriers that remain
Despite optimism, the founder flagged several persistent challenges: unequal access to care, high out-of-pocket costs, and slow uptake of promising new approaches in community clinics. Rural patients and those without robust insurance plans still face delay in receiving advanced therapies or enrolling in trials.
Research funding is improving but competitive. Translational projects—moving lab discoveries into human trials—are costly and risky, and they often need bridge funding that traditional grant cycles don’t provide.
What to watch next
Researchers and funders the founder supports are watching a few areas closely over the next 12–24 months: whether remyelination candidates demonstrate meaningful functional recovery in human trials, how long-term safety profiles for newer immunotherapies evolve, and whether biomarkers can reliably predict who will benefit most from specific treatments.
For patients and families, those developments will influence clinical decision-making and quality-of-life planning. For the broader public, they’ll determine when and how new therapies move from academic centers into everyday neurology clinics.
Practical implications for patients
Her advice for people living with MS is pragmatic: seek care at centers that offer a range of treatment options, ask about clinical-trial eligibility early, and prioritize plans that cover specialty neurology. She also urged patients to be advocates for themselves in conversations about risk tolerance and long-term goals.
“Scientific breakthroughs matter,” she said, “but so does making sure people can access and afford what works.”
Quick snapshot
- Expanded treatment options have reduced relapses for many patients.
- Repair-focused research is gaining funding but remains in early stages.
- Access and affordability continue to shape who benefits from new therapies.
- Translational funding is a bottleneck for bringing lab discoveries to clinical trials.
As Race to Erase MS marks another cycle of grant awards and campaigns, its founder’s message is both hopeful and practical: the science is moving forward, but achieving widespread, durable recovery for people with MS will require sustained investment, smarter trial design and policies that broaden access. That combination—scientific ambition paired with patient-centered advocacy—remains the organization’s defining focus.
